Search filters

Filters
Clear All

Phase

  • 33
  • 94
  • 1
  • 80
  • 37
  • 1
  • 114
  • 382
  • 175
  • 13
  • 19
  • 350
  • 377
  • 5
  • 1
  • 381

Found 382 oncology trials

A listing of oncology medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

 Study Evaluating the Efficacy of Synergo  Radiofrequency-Induced Thermochemotherapy Effect (RITE) with Mitomycin C (Synergo  RITE + MMC) in CIS Non-Muscle Invasive Bladder Cancer (NMIBC)
18 years - 99 years
All genders
Phase 3
The objectives of the study are to determine the efficacy and safety of Synergo® RITE and mitomycin C (MMC) in the treatment of carcinoma in situ (CIS) non-muscle invasive bladder cancer in adult patients who didn't respond to 2 courses of treatment with Bacillus Calmette-Guérin (BCG) installations. The Synergo® system …
 2D AND 4D CONTRAST-ENHANCED ULTRASOUND EVALUATION OF HEPATOCELLULAR CARCINOMA CHEMOEMBOLIZATION
99 years or below
All genders
This is an open-label, non-randomized trial that will be conducted at three clinical sites. The subject population will be patients undergoing transarterial chemoembolization (TACE) for the treatment of hepatocellular carcinoma (HCC) at Thomas Jefferson University, The University of California, San Diego, and University of Pennsylvania. Patients will receive a contrast-enhanced …
99 years or below
All genders
Phase 3
This study will involve patients with high risk non-muscle invasive bladder cancer (NMIBC) that is persistent (cancer stays) or recurrent (cancer comes back) following Bacillus Calmette-Guérin BCG treatment. The purpose of this study is to: o Test the safety of the study drugs, pembrolizumab in combination with Bacillus Calmette-Guerin (BCG) …
18 years - 99 years
All genders
Phase 3
Interventional
This research study is being done to see if patients taking the study drug abelacimab have fewer bleeding events compared to those taking dalteparin. Your participation will last for about 8 months (6 months of treatment and 2 months of follow up). Participants may be paid up to a total …
 Multimodality MRI and Liquid Biopsy in Gliblastoma
18 years - 99 years
All genders
Phase 1
We are seeking to enroll up to 30 subjects with newly diagnosed or recurrent GBM who will undergo a clinical brain MRI examination with and without contrast prior to surgery. Participants will also have a blood draw pre-operatively to collect samples for cfDNA and ctDNA analysis. MRI imaging will include …
 SOROCk- NRG-CC008 A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-Oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers
35 years - 50 years
Female
The main purpose of this study is to determine if two surgical procedures, the usual approach of removing the fallopian tubes and ovaries and the other approach of removing the fallopian tubes at this time with the plan to remove the ovaries at a later time, are no different for …
18 years - 99 years
All genders
Phase 3
The purpose of this study is to compare any good and bad effects of using 2 years of the investigational drug Palbociclib in combination with standard anti-hormone therapy to using standard anti-hormone therapy alone and to evaluate the likelihood that invasive breast cancer returns.
 Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients
18 years - 99 years
All genders
Phase 3
Interventional
The purpose of this study is to test the effectiveness and tolerability of the combination of Nivolumab and Ipilimumab compared to Pemetrexed and Cisplatin or Carboplatin in patients with unresectable pleural mesothelioma.
 UPCC 24420: ULTRA-V: Phase 2 Study to Assess the Efficacy and Safety of Ublituximab in Combination with Umbralisib and Venetoclax (U2-V) in Subjects with Chronic Lymphocytic Leukemia (CLL)
18 years - 99 years
All genders
Phase 2
This study tests the safety and effectiveness of the combination of ublituximab, umbralisib, and venetoclax. Patients with Chronic Lymphocytic Leukemia (CLL) will be invited to participate in this trial.
131 - 140 of 382